Navigation Links
Emdeon Acquires eRx Network, LLC
Date:7/2/2009

an utilization and the implementation of electronic health records with ePrescribing functionality(1). In combination with these initiatives and broader commercial recognition, industry sources project that ePrescribing will accelerate considerably in the coming years.

"This is an exciting time to be in the pharmacy services business and in healthcare overall," commented Mark Lyle, chief executive officer of eRx who has been named Senior Vice President of Emdeon's combined pharmacy services operation. "Our relentless focus on delivering value for our customers has enabled eRx to thrive as a standalone innovator, but this is the right time to align our pharmacy-centric platform with Emdeon's reach across all healthcare sectors. We are confident that Emdeon's resources will allow our combined operations to accelerate new product introductions that will continue driving greater efficiency for our customers and across healthcare."

The new combined operation, to be called eRx Network, an Emdeon Company, will provide pharmacies and healthcare constituents with integrated tools for managing efficiency and profitability through innovative claims management, business intelligence and network infrastructure. By leveraging the capabilities inherent in Emdeon's data and network assets, Emdeon will combine eRx's advanced technology and range of services with its existing suite of pharmacy solutions to form an expanded pharmacy services operation with the same reliability and customer service that is eRx's hallmark.

"By providing expanded pharmacy solutions at this crucial time for our industry, Emdeon is further demonstrating its commitment to making healthcare more efficient. We look forward to working with eRx, our customers and the rest of the industry to create meaningful improvements as the healthcare reform process continues to unfold," Lazenby said.

About eRx Network, LLC

eRx
'/>"/>

SOURCE Emdeon
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Emdeon Assistant Earns HFMA Peer Reviewed Certification for Second Year in a Row
2. Emdeon Announces Agreement to Acquire The Sentinel Group, a Leader in Healthcare Fraud and Abuse Management Services
3. Emdeon Convenes Industry Forum to Monitor Business Efficiency in Healthcare
4. Emdeon Selected by the Maryland Hospital Association to Power the Maryland Transaction Data Interchange
5. Nashvilles Emdeon Business Services to Co-Sponsor Democratic National Convention Health Policy Event
6. Emdeon Assistant Earns HFMAs Peer Review Designation
7. Emdeon Business Services Processes One Billionth Pharmacy Claim for Department of Defense and the U.S. Military Health System
8. Emdeon Business Services Names Miriam Paramore Senior Vice President of Corporate Strategy
9. General Atlantic and Hellman & Friedman Purchase HLTH Corporations Remaining Interest in Emdeon
10. HLTH Corporation Sells its Minority Interest in Emdeon Business Services to General Atlantic and Hellman & Friedman for $575 Million
11. Emdeon Business Services Extends Market Leadership With New Dental Eligibility Payers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Cumberland Pediatric Dentistry and Orthodontics ... values anxiety-free dental care for children, while maintaining the ... dental care. , The orthodontic team is committed ... adolescents, adults and those with special needs. Whether a ... require unique care, such as cleft palate, Cumberland Pediatric ...
(Date:7/22/2014)... (July 22, 2014) With over 170,000 students ... being exposed to injuries during practice and competition, according ... Public Health and the Center for Injury Research and ... The study, published online today by The American ... lacrosse players experienced 1,406 injuries over the four academic ...
(Date:7/22/2014)... July 22, 2014 Garland’s new ... designed to be used as a flood coat over ... or as a premium restoration material. It provides natural ... long-term performance and reducing life-cycle costs. Energizer BK is ... provide excellent water resistance in addition to superior strength ...
(Date:7/22/2014)... CareTouch Communications, Inc. has formed a ... Community . CareTouch employees will select causes they are ... in line with their mission to help people in ... first cause is Hike for Hospice, to benefit the ... September 14, the CareTouch in the Community team will ...
(Date:7/22/2014)... Most people encounter the same two problems when trying to ... is a fast metabolism. These are hard problems to counteract on ... help fight these problems and to finally gain weight. , The ... who just can’t seem to eat more than a couple bites ... cause of this problem can vary. For some it can be ...
Breaking Medicine News(10 mins):Health News:Cumberland Pediatric Dentistry and Orthodontics of Clarksville Welcomes Dr. Peter Wojtkiewicz, Pediatric Orthodontist 2Health News:Cumberland Pediatric Dentistry and Orthodontics of Clarksville Welcomes Dr. Peter Wojtkiewicz, Pediatric Orthodontist 3Health News:High school lacrosse players at risk of concussions other injuries 2Health News:High school lacrosse players at risk of concussions other injuries 3Health News:Energizer® BK Waterproof Coating from Garland Canada Reduces Life-Cycle Costs 2Health News:CareTouch is a Peak Sponsor for the 9th Annual Hike for Hospice in Morrison, Colorado 2Health News:CB-1 Weight Gainer Provides Two Tips to Help Customers Gain Weight 2
... **SAVE THE DATE** April 14-16, 2009 in ... www.worldhealthcarecongress.com WOBURN, Mass., Feb. 19 At ... top leaders and innovators who are driving the $2.4 ... Safeway, Carlson Companies and Kelly Services who are responsible ...
... Industry Veteran Will Lead Company in Development of ,Next ... 19 Valensa International has appointed Dr. Rudi E. ... company. The move to add CEO duties for Dr. ... Parry Nutraceuticals (Division of E.I.D. Parry (India) Ltd, Chennai, ...
... of ApoE4 gene in offspring makes a difference, study finds, ... parents had Alzheimer,s and who carry the so-called Alzheimer,s gene ... older, a new study has found. , This memory decline ... had Alzheimer,s but who do not carry the gene, ...
... VAR ) today announced that it has received ... to help doctors to improve,treatments and outcomes in many cancer ... radiation to control and manage tumors while,significantly reducing damage to ... "CE mark is an important milestone in Varian,s initiative to ...
... BOSTON, Feb. 19 Solos Endoscopy, Inc. (Pink ... Company,s breast endoscopy product line, the MammoView(TM), ... Surgical Products Magazine in the December 2008 issue. ... allow Physicians direct visualization, while examining lesions in ...
... SAN FRANCISCO, Calif., Feb. 19 Poniard Pharmaceuticals, Inc. ... on the development of innovative oncology products, today announced ... and senior vice president, effective February 18, 2009. Mr. ... operations of the Company. "Mr. Weaver has broad experience ...
Cached Medicine News:Health News:6th Annual World Health Care Congress to Convene Preeminent Leaders for Three Days on Rebuilding Health Care 2Health News:6th Annual World Health Care Congress to Convene Preeminent Leaders for Three Days on Rebuilding Health Care 3Health News:Valensa International's Dr. Rudi E. Moerck Appointed CEO 2Health News:If Parents Had Alzheimer's, Aging May Come Early 2Health News:If Parents Had Alzheimer's, Aging May Come Early 3Health News:Varian Medical Systems Has Received CE Mark for Proton Therapy System 2Health News:Solos Endoscopy, Inc.'s MammoView(TM) Featured in December Issue of Surgical Products Magazine 2Health News:Poniard Pharmaceuticals Announces Appointment of Greg Weaver as Chief Financial Officer 2Health News:Poniard Pharmaceuticals Announces Appointment of Greg Weaver as Chief Financial Officer 3
(Date:7/21/2014)... LA JOLLA, Calif. , July 21, 2014 ... RGLS ), a biopharmaceutical company leading the discovery ... today that the U.S. Food & Drug Administration ... a single stranded, chemically modified oligonucleotide that binds ... as a therapeutic for the treatment of Alport ...
(Date:7/21/2014)... , July 21, 2014  Valeant Pharmaceuticals ... (TSX: VRX) has contacted both the Autorite des ... and the U.S. Securities and Exchange Commission ... ) apparent attempt to mislead investors and manipulate ... to make false and misleading statements regarding Valeant,s ...
(Date:7/21/2014)... , July 21, 2014  CASI Pharmaceuticals, Inc. (Nasdaq: ... therapeutics for the treatment of cancer and other diseases, ... and Drug Administration (CFDA) has approved the Company,s application ... breast cancer (TNBC) patients in China ... Ken K. Ren , Ph.D., CASI,s Chief ...
Breaking Medicine Technology:Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 2Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 3Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 4Regulus Receives Orphan Drug Designation for RG-012, a microRNA Therapeutic for the Treatment of Alport Syndrome 5Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 2Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 3Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 4Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 5Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 6Valeant Pharmaceuticals Contacts Quebec and U.S. Regulators About Allergan's False and Misleading Statements 7CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase II Clinical Trial With ENMD-2076 For Triple-Negative Breast Cancer In China 2CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase II Clinical Trial With ENMD-2076 For Triple-Negative Breast Cancer In China 3CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase II Clinical Trial With ENMD-2076 For Triple-Negative Breast Cancer In China 4
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
Used in conjunction with the E5381 600 Circling Band (40 style). Indications: Narrow scleral bed. Overall length: 100 mm, 3.9 inches....
...
...
Medicine Products: